Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 07-22 21:33:05时区推断·⟳ 抓取 07-22 21:34:32·⚡ 决策 07-23 08:34:55 +11h00m·96.5 天前
Iovance股价创52周高位并回顾澳大利亚条件批准等旧消息
正文核心是股价达到5.64美元52周高位，并回顾一季度业绩不及预期和Amtagvi澳大利亚条件批准。
📄 原文Investing.com↗ 原文
Iovance Biotherapeutics stock hits 52-week high at $5.64
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? Iovance Biotherapeutics Inc. stock reache…
不做 Iovance Biotherapeutics（IOVA.US）
该条为股价高位与旧进展汇总，且已有大幅上涨；没有新增可量化事件。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 high ↗
关键理由
- 正文核心是股价达到5.64美元52周高位，并回顾一季度业绩不及预期和Amtagvi澳大利亚条件批准。
主要风险
- 没有披露新的监管批准、销售数据或临床结果；澳大利亚批准属于近期旧闻回顾。
原文全文
展开原文 · 2,296 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Iovance Biotherapeutics Inc. stock reached a 52-week high of $5.64, marking a significant milestone for the company. Currently trading at $5.52, the stock has delivered an impressive 75% return over the past year, significantly outpacing the initially reported figures. The momentum has been particularly strong in recent months, with a 104% surge over the past six months and a 101% gain year-to-date. According to InvestingPro Tips, the stock is trading near its 52-week high with high returns over the last year. This upward trajectory reflects positive investor sentiment and potential advancements in the company’s biotherapeutic developments. With a market capitalization of $2.45 billion and revenue of $285.61 million showing 34% growth, the company appears undervalued according to InvestingPro analysis. For deeper insights, investors can access comprehensive Pro Research Reports covering IOVA and 1,400+ other US equities. As Iovance continues to make strides in its field, the stock’s performance will be closely monitored by investors and analysts alike.
In other recent news, Iovance Biotherapeutics reported its first-quarter 2026 earnings, showing a larger-than-expected loss per share and revenue shortfall. The company reported an earnings per share of -$0.19, missing analysts’ forecasts of -$0.14. Revenue for the quarter reached $71.4 million, falling short of the projected $80.93 million. Additionally, Australia’s Therapeutic Goods Administration granted conditional approval for Iovance’s melanoma therapy, Amtagvi, for adult patients with advanced melanoma. This approval is for patients previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Furthermore, Citizens reiterated a Market Outperform rating for Iovance Biotherapeutics, maintaining a $5.00 price target. The firm highlighted that presentations at ASCO broadened the commercial and clinical case for Amtagvi. These presentations included data on efficacy, safety, workflow, health-related quality of life, and long-term survival analyses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Iovance Biotherapeutics Inc. stock reached a 52-week high of $5.64, marking a significant milestone for the company. Currently trading at $5.52, the stock has delivered an impressive 75% return over the past year, significantly outpacing the initially reported figures. The momentum has been particularly strong in recent months, with a 104% surge over the past six months and a 101% gain year-to-date. According to InvestingPro Tips, the stock is trading near its 52-week high with high returns over the last year. This upward trajectory reflects positive investor sentiment and potential advancements in the company’s biotherapeutic developments. With a market capitalization of $2.45 billion and revenue of $285.61 million showing 34% growth, the company appears undervalued according to InvestingPro analysis. For deeper insights, investors can access comprehensive Pro Research Reports covering IOVA and 1,400+ other US equities. As Iovance continues to make strides in its field, the stock’s performance will be closely monitored by investors and analysts alike.
In other recent news, Iovance Biotherapeutics reported its first-quarter 2026 earnings, showing a larger-than-expected loss per share and revenue shortfall. The company reported an earnings per share of -$0.19, missing analysts’ forecasts of -$0.14. Revenue for the quarter reached $71.4 million, falling short of the projected $80.93 million. Additionally, Australia’s Therapeutic Goods Administration granted conditional approval for Iovance’s melanoma therapy, Amtagvi, for adult patients with advanced melanoma. This approval is for patients previously treated with a PD-1 blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Furthermore, Citizens reiterated a Market Outperform rating for Iovance Biotherapeutics, maintaining a $5.00 price target. The firm highlighted that presentations at ASCO broadened the commercial and clinical case for Amtagvi. These presentations included data on efficacy, safety, workflow, health-related quality of life, and long-term survival analyses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。